United Therapeutics

Beta Technologies specializes in the design and development of electric aircraft, including advanced flight control and electric propulsion systems, with a strong emphasis on clean aviation technology. The company aims to establish a new paradigm for transporting goods and people through its self-sufficient electric vertical takeoff and landing (eVTOL) aircraft ecosystem. This ecosystem is designed to meet human mobility needs while adhering to environmental principles. Additionally, Beta Technologies is working on a comprehensive electric transportation system that features net-zero, all-electric aircraft and a multimodal charging infrastructure to support various electric vehicles. The company also offers training programs for pilots and maintenance personnel, catering to clients in the cargo, passenger, and emergency response sectors, and enabling them to implement more efficient, cleaner, and faster transportation solutions.

SteadyMed Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapeutic products for pain relief and chronic conditions. The company is known for its PatchPump, a customizable, pre-filled, and pre-programmed disposable delivery platform designed for large volume and viscous formulations. Key offerings include Trevyent, a single-use PatchPump pre-filled with treprostinil for treating pulmonary arterial hypertension, and SMT-201, which enables subcutaneous delivery of Ketorolac, a non-steroidal anti-inflammatory drug. Additionally, SMT-301 delivers bupivacaine directly into surgical wounds for effective local pain relief. Founded in 2005 and headquartered in San Ramon, California, with a research and development center in Rehovot, Israel, SteadyMed operates as a subsidiary of United Therapeutics Corporation. The company collaborates with pharmaceutical and device partners to tailor applications of its drug-infusion patches to meet specific therapeutic needs.

Celularity is a clinical-stage biotechnology company focused on advancing cellular medicine through the development of off-the-shelf placental-derived allogeneic cell therapies. Its product pipeline includes unmodified and genetically modified natural killer (NK) cells, CAR-engineered T cells, and mesenchymal-like adherent stromal cells. The company targets various health conditions, including cancer, immunologic disorders, infectious diseases, and degenerative illnesses. Celularity leverages the unique biology of the placenta, aiming to create effective and accessible therapies to address significant unmet medical needs. In addition to its cell therapy initiatives, Celularity operates a bio-banking segment, which contributes substantially to its revenue.

The University of Alabama at Birmingham (UAB) is a prominent institution located in Birmingham, Alabama, established in 1969. It offers a wide range of academic programs, with over 130 areas of study, including bachelor's, master's, doctoral, and professional degrees across various disciplines such as arts, sciences, business, education, engineering, and public health. UAB is particularly recognized for its medical school and one of the largest university medical centers in the United States. The university boasts a diverse student body, including many distinguished scholars who have received prestigious awards. UAB fosters a vibrant student life with over 150 organizations, active Greek life, and comprehensive recreational facilities. Financial aid and departmental fellowships are available to help eligible students cover tuition costs. UAB's mission extends beyond education, serving the community and addressing global challenges through research and innovation.

Revivicor is a regenerative medicine company that specializes in xenotransplantation, utilizing gene-edited pigs to address the significant shortage of human organs available for transplantation. By leveraging advanced animal biotechnology, Revivicor aims to create a reliable and high-quality source of human-compatible tissues, which can be used in the treatment of various degenerative diseases. The company is dedicated to overcoming the challenges associated with organ scarcity, providing innovative solutions that could enhance the quality of life for patients in need of transplants.

Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.

Medicomp specializes in the development, manufacture, and servicing of advanced ambulatory heart-monitoring systems. The company focuses on the cardiac telemedicine and home sleep testing markets, utilizing diagnostic technologies and proprietary Diogenes algorithms to deliver comprehensive beat-to-beat analyses of cardiac activity, including P-wave assessment, rate, rhythm, and QRS morphology. Medicomp provides detailed patient reports, facilitates remote monitoring, and ensures integration with electronic medical records, enhancing the overall efficiency of cardiac care.

Cooke Pharma is a privately held company and is the exclusive maker of the HeartBar line of arginine-enriched products.

SynQuest, Inc. is a company that manufactured treprostinil, the bulk active ingredient in Remodulin.